MannKind Corp. (NASDAQ:MNKD) granted Sanofi (Euronext:SAN; NYSE:SNY) exclusive, worldwide rights to develop and commercialize Afrezza inhaled insulin to treat adults with Type I and II diabetes.
MannKind licenses Afrezza to Sanofi
Products & Solutions
About Biocentury
Contact
Privacy & Legal
- Follow Us
